How to Get Praluent (Alirocumab) in Delaware

What Is Praluent and Why Does It Matter for Delaware Patients?

Praluent (alirocumab) is a fully human monoclonal antibody that blocks PCSK9, the protein that degrades LDL receptors on liver cells. By preserving those receptors, alirocumab drives LDL cholesterol down by 45 to 62 percent depending on dose and baseline lipid status. The FDA granted alirocumab approval in July 2015 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL lowering beyond maximally tolerated statin therapy [1].

Delaware has a cardiovascular disease burden consistent with national trends. The CDC reports that heart disease remains the leading cause of death among Delaware adults, making effective LDL management a clinical priority for the state's roughly 1 million residents [2]. Alirocumab addresses the patients for whom statins alone are insufficient: those with HeFH, those who have survived an acute coronary syndrome (ACS) event, or those who cannot tolerate adequate statin doses because of myopathy or other adverse effects.

The key ODYSSEY LONG TERM trial (N=2,341) demonstrated a 61.9% reduction in LDL-C from baseline at 24 weeks with alirocumab 150 mg every two weeks compared to 0.8% with placebo (P<0.001) [3]. That degree of LDL reduction translates into meaningful cardiovascular risk reduction when sustained over time, a point confirmed by the larger ODYSSEY OUTCOMES trial discussed below.

Prescribers in Delaware, whether practicing in Wilmington cardiology offices or providing care through a telehealth platform, can write for alirocumab under the same clinical criteria. The state does not impose additional licensure requirements for this drug class beyond a valid Delaware DEA-exempt prescribing license and compliance with federal REMS guidelines (no REMS is currently active for alirocumab, but prescribers must document clinical indication).

ODYSSEY OUTCOMES: The Clinical Evidence Behind Every Praluent Prescription

The ODYSSEY OUTCOMES trial is the cornerstone evidence base that insurers, including Delaware Medicaid, cite when drafting coverage criteria for alirocumab. Published in the New England Journal of Medicine in 2018, the trial enrolled 18,924 patients who had experienced an ACS event 1 to 12 months before randomization [4]. Participants were already receiving high-intensity statin therapy.

Alirocumab reduced the primary composite endpoint (coronary heart disease death, non-fatal MI, fatal or non-fatal ischemic stroke, or unstable angina requiring hospitalization) by a relative 15% compared to placebo (hazard ratio 0.85 to 95% CI 0.78 to 0.93, P<0.001) [4]. In the subgroup with baseline LDL-C of 100 mg/dL or higher, the absolute risk reduction reached 3.4 percentage points over a median 2.8 years of follow-up.

All-cause mortality was also numerically lower in the alirocumab arm (3.5% vs 4.1%, HR 0.85 to 95% CI 0.73 to 0.98) [4]. The ACC/AHA 2018 Guideline on the Management of Blood Cholesterol states directly: "In patients with very high-risk ASCVD who require additional LDL-C lowering despite maximally tolerated statin therapy and ezetimibe, a PCSK9 inhibitor may be considered" [5]. Delaware insurers use this language verbatim in their prior authorization (PA) criteria, so understanding it helps patients and prescribers build a compliant PA submission.

The European Heart Journal 2019 dyslipidaemia guidelines assign a Class I, Level A recommendation to PCSK9 inhibitors for very-high-risk patients who do not reach LDL-C goals on maximum tolerated statin plus ezetimibe, reinforcing the global consistency of this evidence [6]. When a Delaware insurer denies a PA on the grounds of "insufficient clinical need," citing ODYSSEY OUTCOMES directly in the appeal often reverses that decision.

Who Can Prescribe Praluent in Delaware?

Any Delaware-licensed physician (MD or DO), nurse practitioner (NP), or physician assistant (PA) with prescriptive authority may write for alirocumab. There is no specialty restriction at the state level, though most plans prefer or require that the prescribing clinician be a cardiologist, endocrinologist, or lipid specialist, particularly for the FH indication.

Delaware adopted the full Nurse Practice Act amendments in 2012 that grant advanced practice registered nurses (APRNs) full independent prescriptive authority without a collaborative agreement requirement, consistent with the National Academy of Medicine recommendations [7]. This is clinically significant because it broadens the prescriber pool to NP-led telehealth practices operating in the state.

PA prescriptive authority in Delaware requires a supervising physician agreement, but the supervising physician does not need to co-sign each alirocumab prescription. The agreement covers the PA's scope of practice, including lipid management. Pharmacies and specialty distributors in Delaware accept alirocumab prescriptions from qualified NPs and PAs without additional verification beyond the standard DEA number and state license number.

Telehealth prescribers must hold a valid Delaware license or qualify under the interstate compact. The Interstate Medical Licensure Compact (IMLC) and the Nurse Licensure Compact (NLC) both include Delaware as a member state [8], meaning that a compact-licensed clinician in another state can prescribe alirocumab to a Delaware patient following a compliant telehealth visit, which includes a synchronous audio-video encounter as required under Delaware Code Title 24.

What Lab Work Is Required Before Starting Praluent?

Before any prescriber writes for alirocumab, a baseline fasting lipid panel is required. The panel should include total cholesterol, LDL-C (calculated or direct), HDL-C, triglycerides, and non-HDL-C. LDL-C values that typically trigger PCSK9 inhibitor eligibility under most Delaware insurer criteria are 70 mg/dL or above on maximally tolerated statin therapy for ASCVD patients, or 100 mg/dL or above for HeFH patients [5].

Additional labs that strengthen the prior authorization file include a fasting glucose or HbA1c (to document metabolic context), a comprehensive metabolic panel (to rule out hepatic contraindications), and a creatine kinase (CK) level if statin intolerance is part of the clinical story. Genetic testing for LDLR, APOB, or PCSK9 mutations is not required to diagnose HeFH clinically, but a positive genetic result removes ambiguity during PA reviews and appeals.

The ACC recommends checking LDL-C 4 to 12 weeks after initiating a PCSK9 inhibitor to assess response and dose-titrate if needed [5]. Alirocumab's 75 mg starting dose may be doubled to 150 mg every two weeks if the 4 to 12-week LDL-C remains above the patient's individualized target. Labs should be drawn at a Delaware-licensed clinical laboratory; telehealth platforms typically integrate with LabCorp or Quest Diagnostics locations statewide for patient convenience.

Thyroid function (TSH) is sometimes ordered alongside a lipid panel because hypothyroidism is a reversible secondary cause of hypercholesterolemia. Ruling it out before attributing elevated LDL-C entirely to FH or ASCVD-related residual risk avoids prescribing alirocumab to a patient who simply needs levothyroxine dose optimization.

Delaware Telehealth and How to Get a Praluent Prescription Online

Delaware permits synchronous telehealth prescribing for non-controlled substances, and alirocumab is not a controlled substance. A Delaware resident can complete an online visit with a licensed prescriber, review lab results electronically, and receive a Praluent prescription sent directly to a specialty pharmacy, all without visiting a physical office.

The Delaware Health and Social Services telemedicine guidance, aligned with the federal 21st Century Cures Act, requires that telehealth prescribing encounters for new prescriptions include a real-time audio-video interaction. Asynchronous "store-and-forward" prescribing alone is not sufficient for a first alirocumab prescription in Delaware [9]. Follow-up refills may use asynchronous messaging once the prescriber-patient relationship is established.

Platforms that prescribe alirocumab in Delaware typically follow this workflow: (1) patient completes intake form including lipid history, statin trial documentation, and current medications; (2) lab order is placed at a local draw site; (3) provider reviews results and conducts a live video visit; (4) prescription is transmitted electronically to a specialty pharmacy such as Accredo, CVS Specialty, or Walgreens Specialty; (5) specialty pharmacy initiates prior authorization with the patient's insurer; (6) drug ships by cold-chain courier to the patient's Delaware address.

Most telehealth visits for alirocumab take 20 to 30 minutes. Patients should gather their last two to three lipid panels, documentation of statin trials (drug name, dose, duration, and reason for discontinuation), and any prior authorization denial letters before the visit. Having this documentation cuts the visit time and accelerates the PA submission.

The HealthRX Delaware Praluent Access Framework identifies four patient categories that typically qualify for telehealth prescribing of alirocumab in the state: (A) post-ACS patients on high-intensity statin with LDL-C remaining at or above 70 mg/dL; (B) HeFH patients on maximally tolerated statin with LDL-C at or above 100 mg/dL; (C) statin-intolerant patients with documented myopathy or rhabdomyolysis history and LDL-C at or above 100 mg/dL; (D) patients with both diabetes and established ASCVD whose LDL-C exceeds 55 mg/dL per ESC/EAS very-high-risk thresholds [6]. Each category requires slightly different prior authorization documentation, as outlined in the section below.

Prior Authorization in Delaware: What Documents You Need

Delaware insurers, including Highmark Blue Cross Blue Shield of Delaware, Aetna, UnitedHealthcare, and Delaware Medicaid (administered through Molina, AmeriHealth Caritas, and other managed care organizations), require prior authorization for alirocumab. The typical PA packet includes the following elements.

First, the prescriber submits the patient's most recent lipid panel showing LDL-C above the threshold for the indication, dated within the past 12 months. Second, the prescriber documents at least one (often two) high-intensity statin trials, naming the specific statins (atorvastatin 40 to 80 mg, rosuvastatin 20 to 40 mg), durations tried, and reason for failure, whether inadequate efficacy or intolerance. Third, the prescriber confirms that ezetimibe 10 mg daily was tried for at least 90 days and either failed to achieve goal or was not tolerated. The ACC/AHA 2018 guidelines specify ezetimibe as the first add-on therapy before a PCSK9 inhibitor in most patients [5], and insurers follow this sequence strictly.

Fourth, for FH-specific PAs, the prescriber must document clinical FH diagnosis using the Dutch Lipid Clinic Network (DLCN) criteria or Simon Broome criteria, or provide genetic testing results [10]. A DLCN score of 6 or higher (probable FH) or 8 or higher (definite FH) satisfies most Delaware insurer requirements. Fifth, the prescriber provides CPT and ICD-10 codes: E78.01 (FH) or Z87.39/I25.10 for ASCVD, paired with Z79.899 for long-term use of other medication.

Delaware Medicaid prior authorizations are submitted through the Delaware Medical Assistance Portal (DMAP). Commercial insurer PAs go through CoverMyMeds, Surescripts, or the insurer's own portal. Most specialty pharmacies handling alirocumab (Accredo, CVS Specialty) offer PA support services and will file the PA on behalf of the prescriber after receiving the prescription.

PA approvals in Delaware typically require 3 to 7 business days for standard review. Urgent review (for post-ACS patients still hospitalized or recently discharged) may be processed in 24 to 72 hours. Appeals of initial denials have a 30-day window under Delaware insurance regulations and should include ODYSSEY OUTCOMES data and the ACC/AHA guideline language cited above.

Pharmacy Fulfillment and 503A Compounding in Delaware

Alirocumab is a biologic manufactured under strict cold-chain conditions. Brand Praluent is available through Sanofi's specialty pharmacy network and major specialty pharmacy chains. Delaware patients typically receive the drug by 2-day cold-chain shipping to their home address. The pen device (auto-injector) arrives pre-filled and requires refrigeration at 2 to 8 degrees Celsius; it can be stored at room temperature (below 25 degrees Celsius) for up to 30 days before use [1].

Delaware-licensed 503A compounding pharmacies may compound alirocumab analogs for patient-specific prescriptions, though this path is rarely used in clinical practice given the FDA-approved biologic's availability and the complexity of compounding monoclonal antibodies. The FDA's guidance on biological compounding makes clear that compounded versions of approved biologics face a high regulatory bar [11]. For the vast majority of Delaware patients, brand Praluent through a specialty pharmacy is the appropriate and expedient route.

Manufacturer patient-assistance programs offer significant cost relief. Sanofi's Praluent My Support 360 program provides eligible commercially insured patients with co-pay assistance bringing monthly out-of-pocket costs to as low as zero dollars, subject to income and insurance eligibility criteria [12]. Uninsured or underinsured Delaware patients may qualify for Sanofi's patient assistance program, which provides Praluent at no cost. The HealthRX care team can submit the assistance program application simultaneously with the PA submission to minimize delays.

Delaware retail pharmacies (CVS, Walgreens, Rite Aid) do not stock alirocumab as a shelf item because of cold-chain and low-volume inventory constraints. All fulfillment goes through specialty channels. Prescribers should route the e-prescription to Accredo (1-800-803-2523) or CVS Specialty (1-800-237-2767) to avoid delays from a retail pharmacist redirecting the prescription.

Delaware Medicaid Coverage Criteria for Praluent

Delaware Medicaid covers alirocumab for both HeFH and established ASCVD indications with prior authorization. The Medicaid Drug Utilization Review (DUR) Board in Delaware has placed PCSK9 inhibitors on the preferred drug list (PDL) as non-preferred agents, meaning PA is required but the drug is accessible once criteria are met [13].

Medicaid PA criteria in Delaware align closely with the ACC/AHA 2018 guidelines: documented diagnosis of HeFH (DLCN score or genetic confirmation) or clinical ASCVD, LDL-C above 70 mg/dL (ASCVD) or 100 mg/dL (HeFH) on maximally tolerated statin, and a documented ezetimibe trial. Medicaid PAs are typically approved for 12 months and require annual re-authorization demonstrating continued clinical need and LDL-C response.

Delaware Medicaid managed care organizations (MCOs) such as Molina Healthcare of Delaware and AmeriHealth Caritas Delaware handle PA requests through their own portals, separate from fee-for-service Medicaid. Prescribers working through telehealth platforms must verify which MCO the patient is enrolled in, as criteria and turnaround times differ slightly between plans.

Transferring an Existing Praluent Prescription to Delaware

Patients moving to Delaware from another state can transfer their alirocumab prescription, though a few practical steps apply. Because alirocumab is a specialty drug fulfilled through specialty pharmacies rather than retail, the transfer is handled pharmacy-to-pharmacy at the specialty level. The patient contacts the original specialty pharmacy, requests a transfer to a Delaware-accessible specialty pharmacy (which, in practice, means any Accredo or CVS Specialty location since they ship nationally), and provides the new Delaware address.

If the prescription was issued by an out-of-state prescriber who does not hold a Delaware license or compact license, a new prescription from a Delaware-licensed prescriber is required. Telehealth platforms covering Delaware can issue this new prescription after a brief chart review and a 20-minute video visit. Most platforms can complete this process within 48 hours of the patient's request.

Insurance transfer is the more complex part of the transition. Delaware Medicaid does not honor prior authorizations issued by another state's Medicaid program. Commercial plan PAs, however, often transfer with the insurance policy if the patient is on a national plan (Aetna, UnitedHealthcare, Cigna). Patients should call their insurer's specialty pharmacy line before relocating to confirm whether the PA follows them to Delaware or needs to be resubmitted.